Drug Eruptions Questions & Answers

1. Ramien M, Goldman JL. Pediatric SJS-TEN: Where are we now?. F1000Res. 2020. 9:[QxMD MEDLINE Link].

2. Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). J Eur Acad Dermatol Venereol. 2020 Aug 26. [QxMD MEDLINE Link].

3. Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, Arias-Santiago S. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. J Am Acad Dermatol. 2020 Aug 7. [QxMD MEDLINE Link].

4. Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. J Cutan Med Surg. 2020 Aug 3. 1203475420943260. [QxMD MEDLINE Link].

5. Silva D, Gomes A, Ms Lobo J, Almeida V, Almeida IF. Management of skin adverse reactions in oncology. J Oncol Pharm Pract. 2020 Oct. 26 (7):1703-1714. [QxMD MEDLINE Link].

6. Monteagudo B, Cabanillas M, Iriarte P, Ramírez-Santos A, León-Muinos E, González-Vilas D, et al. Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?. Acta Dermatovenerol Croat. 2018 Apr. 26 (1):61-63. [QxMD MEDLINE Link].

7. Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol. 2001 Jan. 44(1):100-8. [QxMD MEDLINE Link].

8. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006 Apr. 6(4):543-9. [QxMD MEDLINE Link].

9. Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J. 2008 Feb. 84(988):60-5. [QxMD MEDLINE Link].

10. Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol. 2005 Mar. 136(3):205-16. [QxMD MEDLINE Link].

11. Iannini P, Mandell L, Felmingham J, Patou G, Tillotson GS. Adverse cutaneous reactions and drugs: a focus on antimicrobials. J Chemother. 2006 Apr. 18(2):127-39. [QxMD MEDLINE Link].

12. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993 Jun 10. 328(23):1670-4. [QxMD MEDLINE Link].

13. Taddio A, Lee CM, Parvez B, Koren G, Shah V. Contact dermatitis and bradycardia in a preterm infant given tetracaine 4% gel. Ther Drug Monit. 2006 Jun; 28(3):291-4. Available at http://www.ncbi.nlm.nih.gov/pubmed/16778708.

14. Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized pustular psoriasis: case report and literature review. Available at http://www.ncbi.nlm.nih.gov/sites/entrez/19531936.

15. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol. 2003 Mar. 48(3):439-41. [QxMD MEDLINE Link].

16. Nofal A, El-Din ES. Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?. Int J Dermatol. 2012 May. 51(5):535-41. [QxMD MEDLINE Link].

17. Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010 Feb; 62 (2):315-8. Available at http://www.ncbi.nlm.nih.gov/pubmed/19665822..

18. Kornmehl H, Gorouhi F, Konia T, Fung MA, Tartar DM. Generalized fixed drug eruption to piperacillin/tazobactam and review of literature. Dermatol Online J. 2018 Apr 15. 24 (4):[QxMD MEDLINE Link].

19. Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol. 1998 May-Jun. 16(3):325-32. [QxMD MEDLINE Link].

20. Camilleri M, Pace JL. Drug-induced linear immunoglobulin-A bullous dermatosis. Clin Dermatol. 1998 May-Jun. 16(3):389-91. [QxMD MEDLINE Link].

21. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol. 2004 Mar-Apr. 22(2):157-66. [QxMD MEDLINE Link].

22. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998 May-Jun. 16(3):393-7. [QxMD MEDLINE Link].

23. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol. 2008 Jun. 158(6):1299-307. [QxMD MEDLINE Link].

24. Dika E, Varotti C, Bardazzi F, Maibach HI. Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score. Cutan Ocul Toxicol. 2006. 25(1):1-11. [QxMD MEDLINE Link].

25. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000 May-Jun. 1(3):159-65. [QxMD MEDLINE Link].

26. Clark BM, Kotti GH, Shah AD, Conger NG. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy. 2006 May. 26(5):705-8. [QxMD MEDLINE Link].

27. Romano A, Valluzzi RL, Caruso C, Maggioletti M, Gaeta F. Non-immediate Cutaneous Reactions to Beta-Lactams: Approach to Diagnosis. Curr Allergy Asthma Rep. 2017 Apr. 17 (4):23. [QxMD MEDLINE Link].

28. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008. 40(2):129-38. [QxMD MEDLINE Link].

29. Lee HY, Pang SM, Thamotharampillai T. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol. 2008 Aug. 59(2):352-3. [QxMD MEDLINE Link].

30. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 Dec 14. 333(24):1600-7. [QxMD MEDLINE Link].

31. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant. 2012 Apr 6. [QxMD MEDLINE Link].

32. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010 Mar. 146(3):300-4. [QxMD MEDLINE Link].

33. MacMorran WS, Krahn LE. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics. 1997 Sep-Oct. 38(5):413-22. [QxMD MEDLINE Link].

34. Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallares C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006 Sep. 55(3):429-37. [QxMD MEDLINE Link].

35. Lee JJ, Kroshinsky D, Hoang MP. Cutaneous Reactions to Targeted Therapy. Am J Dermatopathol. 2017 Feb. 39 (2):67-82. [QxMD MEDLINE Link].

36. Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol. 2006 Aug. 55(2):349-53. [QxMD MEDLINE Link].

37. Donovan JC, Ghazarian DM, Shaw JC. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Arch Dermatol. 2008 Nov. 144(11):1524-5. [QxMD MEDLINE Link].

38. Shipley D, Ormerod AD. Drug-induced urticaria. Recognition and treatment. Am J Clin Dermatol. 2001. 2(3):151-8. [QxMD MEDLINE Link].

39. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008 Apr. 58(4):545-70. [QxMD MEDLINE Link].

40. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2011 Jul. 23(4):343-51. [QxMD MEDLINE Link].

41. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Medline. Available at http://www.ncbi.nlm.nih.gov/sites/entrez/18645140.

42. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23. 366(8):707-14. [QxMD MEDLINE Link].

43. Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012 Mar 1. 366(9):866-8. [QxMD MEDLINE Link].

44. Teoh DC, Aw DC, Jaffar H, et al. Tamoxifen-induced eccrine squamous syringometaplasia. J Cutan Pathol. 2012 May. 39(5):554-7. [QxMD MEDLINE Link].

45. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol. 1995 Sep. 33(3):393-410; quiz 410-2. [QxMD MEDLINE Link].

46. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012 May. 39(5):481-92. [QxMD MEDLINE Link].

47. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Medline. Available at http://www.ncbi.nlm.nih.gov/sites/entrez/18486740.

48. Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol. 2013 Feb. 168(2):391-401. [QxMD MEDLINE Link].

49. Yang J, Yang X, Li M. Peripheral blood eosinophil counts predict the prognosis of drug eruptions. J Investig Allergol Clin Immunol. 2013. 23(4):248-55. [QxMD MEDLINE Link].

50. Happel CS. Rash diagnostics: an update on the diagnosis of allergic rashes. Curr Opin Pediatr. 2017 Jun. 29 (3):371-378. [QxMD MEDLINE Link].

51. Helm TN, Liu-Helm AY. Immunomodulation, alemtuzumab associated dermatitis and the histology of drug-induced exanthems. J Cutan Pathol. 2017 Apr. 44 (4):405-406. [QxMD MEDLINE Link].

52. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005 Apr 15. 209(2):209-16. [QxMD MEDLINE Link].

53. Cury-Martins J, Eris APM, Abdalla CMZ, et al. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol. 2020 Mar - Apr. 95 (2):221-237. [QxMD MEDLINE Link]. [Full Text].

Jonathan E Blume, MD Instructor in Clinical Dermatology, Columbia University College of Physicians and Surgeons; Dermatologist, Westwood Dermatology and Dermatologic Surgery Group PA

Jonathan E Blume, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, International Society of Dermatology

Disclosure: Nothing to disclose.

Liaqat Ali, MD Assistant Professor, Department of Dermatology, Wayne State University School of Medicine; Dermatopathologist, Pinkus Dermatopathology Laboratory, Monroe, MI

Liaqat Ali, MD is a member of the following medical societies: American Society for Clinical Pathology, American Society of Dermatopathology, College of American Pathologists, United States and Canadian Academy of Pathology

Disclosure: Nothing to disclose.

Michelle Ehrlich, MD Director of Cosmetic Dermatology and Surgery Residency Program, Harbor-UCLA Medical Center; Clinical Instructor, Department of Dermatology, University of California, Los Angeles, David Geffen School of Medicine

Michelle Ehrlich, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology

Disclosure: Nothing to disclose.

Thomas N Helm, MD Clinical Professor of Dermatology and Pathology, University of Buffalo, State University of New York School of Medicine and Biomedical Sciences; Director, Buffalo Medical Group Dermatopathology Laboratory

Thomas N Helm, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society of Dermatopathology

Disclosure: Nothing to disclose.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: Biogen US (Adjudicator for study entry cutaneous lupus erythematosus); Priovant (Adjudicator for entry into a dermatomyositis study); IQVIA (Serono - adjudicator for a study of cutaneous LE) <br/>Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for these trust accounts for: Stocks held in various trust accounts: Allergen; Amgen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble;; Celgene; Gilead; CVS; Walgreens; Bristol-Myers Squibb.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Neil Shear, MD Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Faculty of Medicine; Head of Dermatology, Sunnybrook Women's College Health Sciences Center and Women's College Hospital, Canada

Neil Shear, MD is a member of the following medical societies: Canadian Medical Association, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, Canadian Dermatology Association, American Academy of Dermatology, American Society for Clinical Pharmacology and Therapeutics

Disclosure: Nothing to disclose.

Charles Camisa, MD Head of Clinical Dermatology, Vice-Chair, Department of Dermatology, Cleveland Clinic Foundation

Charles Camisa, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article